Early Combination Therapy Proven to Reduce Heart Attack Risks

Research confirms that starting statins and ezetimibe within 12 weeks of a heart attack significantly lowers the risk of further cardiovascular events and deaths.

A study of 36,000 Swedish heart attack patients (2015–2022) shows early dual therapy with statins and ezetimibe improves outcomes compared to delayed or single-drug treatments.
Patients receiving the combination therapy within 12 weeks achieved cholesterol targets faster, reducing risks of recurrent heart attacks, strokes, and death.
The findings challenge current stepwise treatment guidelines, which delay achieving cholesterol goals and risk losing patients to follow-up.
Ezetimibe, an affordable and widely available drug with minimal side effects, makes early combination therapy cost-effective and accessible globally.
Swedish hospitals implementing updated treatment algorithms have seen significant improvements in patient outcomes, prompting calls for global guideline revisions.